A CT-based Radiomics Model to Predict Survival-graded Fibrosis in PDAC - Trial NCT06267690
Access comprehensive clinical trial information for NCT06267690 through Pure Global AI's free database. This phase not specified trial is sponsored by First Affiliated Hospital, Sun Yat-Sen University and is currently Completed. The study focuses on Pancreatic Cancer. Target enrollment is 295 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
First Affiliated Hospital, Sun Yat-Sen University
Timeline & Enrollment
N/A
Jan 13, 2021
Aug 31, 2023
Primary Outcome
fibrosis
Summary
Tumor fibrosis plays an important role in chemotherapy resistance in pancreatic ductal
 adenocarcinoma (PDAC), however there remains a contradiction in the prognostic value of
 fibrosis. We aimed to investigate the relationship between tumor fibrosis and survival in
 patients with PDAC, classify patients into high- and low-fibrosis groups, and develop and
 validate a CT-based radiomics model to non-invasively predict fibrosis before treatment.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06267690
Non-Device Trial